fluocinolone


Also found in: Medical, Financial, Encyclopedia, Wikipedia.
Related to fluocinolone: Fluocinolone acetonide
Translations

fluocinolone

n fluocinolona
References in periodicals archive ?
com adds "Global and Chinese Fluocinolone Acetonide Industry, 2010-2020 Market Research Report" latest study of 150 pages, published in Nov 2015, to the Medicine and Pharmacy intelligence collection of its store.
Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide (FAc), a corticosteroid, for 36 months.
Making the recommendation, the NICE Appraisal Committee confirmed that Iluvien, which is also known as fluocinolone, is "clinically effective in the treatment of vision impairment associated with chronic DME.
Food and Drug Administration (FDA) for Iluvien(R), (flucocinolone acetonide intravitreal insert), its investigational, sustained drug delivery system releasing sub- microgram levels of fluocinolone acetonide for the treatment of diabetic macular edema (DME).
The triple therapy group applied fluocinolone acetonide 0.
Amneal Pharmaceuticals, LLC is pleased to announce its new Fluocinolone Acetonide 0.
Alimera's lead product, ILUVIEN Fluocinolone Acetonide (190 micrograms intravitreal implant in applicator), is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection.
European Ophthalmic Review, the peer-reviewed journal, has published a review highlighting the benefits of Real-world Experiences of Fluocinolone Acetonide (0.
Injected into the patient's eye, it delivers sustained sub-microgram levels of fluocinolone acetonide.
The NDA seeks approval to market ILUVIEN (fluocinolone acetonide intravitreal insert), an investigational, sustained drug delivery system that releases sub-microgram levels of fluocinolone acetonide for the treatment of DME.
ILUVIEN Fluocinolone Acetonide (190 micrograms intravitreal implant in applicator) is a sustained release intravitreal implant indicated in the European Union for the treatment of vision impairment associated with chronic diabetic macular edema, considered insufficiently responsive to available therapies.
In 1999, he was given responsibility as site leader for the industrialisation of a new drug application which is now marketed as Retisert, a fluocinolone acetonide intravitreal implant, an advance in the management of chronic non-infectious uveitis affecting the posterior segment of the eye.